EXTON, Pa., March 5, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 11:00 AM ET.
It will also present at the KBCM Healthcare Forum on Wednesday, March 19, 2025 at 1:30 PM ET.
A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximately 90 days after the events.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
Last Trade: | US$229.76 |
Daily Change: | 6.03 2.70 |
Daily Volume: | 555,193 |
Market Cap: | US$16.640B |
February 13, 2025 January 22, 2025 January 06, 2025 December 11, 2024 October 24, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load